Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD – role of umeclidinium/vilanterol

References

• QaseemAWiltTJWeinbergerSEAmerican College of PhysiciansAmerican College of Chest PhysiciansAmerican Thoracic SocietyEuropean Respiratory SocietyDiagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory SocietyAnn Intern Med2011155317919121810710
   PubMed Web of Science ®Google Scholar
• Global Inititaive for Obstructive Lung Disease [homepage on the Internet]Global strategy for the diagnosis, management and prevention of COPD2011 [updated Jan 2014]. Available from: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.htmlAccessed May 18, 2014
   Google Scholar
• DonohueJFOharJABronchodilator therapy of airway diseaseChungKFBarnesPJPharmacology and Therapeutics of Airway DiseaseNew YorkInforma Healthcare USA2009198225
   Google Scholar
• OharJADonohueJFMono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPDSemin Respir Crit Care Med201031332133320496301
   PubMed Web of Science ®Google Scholar
• GrossNJCoESkorodinMSCholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjectsChest19899659849872805869
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFNA News Release12182013 Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm379057.htmAccessed May 18, 2014
   Google Scholar
• SalmonMLuttmannMAFoleyJJPharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseasesJ Pharmacol Exp Ther2013345226027023435542
   PubMed Web of Science ®Google Scholar
• Tal-SingerRCahnAMehtaRInitial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studiesEur J Pharmacol20137011–3404823276660
   PubMed Web of Science ®Google Scholar
• DecramerMMaltaisFFeldmanGBronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patientsRespir Physiol Neurobiol2013185239339923026438
   PubMed Web of Science ®Google Scholar
• TrivediRRichardNMehtaRChurchAUmeclidinium in patients with COPD: a randomised, placebo-controlled studyEur Respir J2014431728123949963
   PubMed Web of Science ®Google Scholar
• MalerbaMRadaeliAMorjariaJBTherapeutic potential for novel ultra long-acting β2-agonists in the management of COPD: biological and pharmacological aspectsDrug Discov Today2012179–1049650422119310
   PubMed Web of Science ®Google Scholar
• BarrettVJEmmonsAFordAJKnowlesRIn vitro pharmacological characterisation of GW642444, a novel long acting β2-agonist (LABA) using human recombinant β1/2/3 adrenoceptor cAMP assays [Abstract]Am J Respir Crit Care Med2010181A4451
   Web of Science ®Google Scholar
• ProcopiouPABarrettVJBevanNJSynthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approachJ Med Chem201053114522453020462258
   PubMed Web of Science ®Google Scholar
• FordAJHughesSSmithCSomersGRanshawLThe therapeutic index of vilanterol trifenatate [Abstract]Eur Respir J201024208s
   Google Scholar
• KempsfordRNorrisVSiedererSGW642444, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), at single doses of 25, 50 and 100 mcg, is well tolerated and demonstrates prolonged bronchodilation in asthmatic patients [Abstract]Am J Respir Crit Care Med2010181A5413
   Web of Science ®Google Scholar
• KempsfordRNorrisVSiedererSGW642444, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), at single doses of 25, 50 and 100 mcg, is well tolerated and demonstrates prolonged bronchodilation in COPD patients [Abstract]Am J Respir Crit Care Med2010181A4447
   Web of Science ®Google Scholar
• KempsfordRNorrisVSiedererSVilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPDPulm Pharmacol Ther201326225626423232038
   PubMed Web of Science ®Google Scholar
• HananiaNAFeldmanGZachgoWThe efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trialChest2012142111912722241764
   PubMed Web of Science ®Google Scholar
• KestenSCelliBDecramerMLeimerITashkinDTiotropium HandiHaler in the treatment of COPD: a safety reviewInt J Chron Obstruct Pulmon Dis2009439740920037679
   PubMedGoogle Scholar
• KizerKMBessDTBedfordNKBlurred vision from ipratropium bromide inhalationAm J Health Syst Pharm199956991410344619
   PubMed Web of Science ®Google Scholar
• MulpeterKMWalshJBO’ConnorMO’ConnellFBurkeCOcular hazards of nebulized bronchodilatorsPostgrad Med J1992687961321331533281
   PubMed Web of Science ®Google Scholar
• PrasEStienlaufSPinkhasJSidiYUrinary retention associated with ipratropium bromideDICP19912599399401835224
   PubMedGoogle Scholar
• StephensonASeitzDBellCMInhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease: a population-based studyArch Intern Med20111711091492021606096
   PubMedGoogle Scholar
• MannJSHowarthPHHolgateSTBronchoconstriction induced by ipratropium bromide in asthma: relation to hypotonicityBr Med J (Clin Res Ed)19842896443469
   Web of Science ®Google Scholar
• LeeTAPickardASAuDHBartleBWeissKBRisk for death associated with medications for recently diagnosed chronic obstructive pulmonary diseaseAnn Intern Med2008149638039018794557
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSUPLIFT Study InvestigatorsA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• SinghSLokeYKEnrightPLFurbergCDMortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trialsBMJ2011342d321521672999
   PubMed Web of Science ®Google Scholar
• WiseRAAnzuetoACalverleyPThe Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationaleRespir Res2013144023547660
   PubMed Web of Science ®Google Scholar
• WiseRAAnzuetoACottonDTIOSPIR InvestigatorsTiotropium Respimat inhaler and the risk of death in COPDN Engl J Med2013369161491150123992515
   PubMed Web of Science ®Google Scholar
• TashkinDPFabbriLMLong-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agentsRespir Res20101114921034447
   PubMed Web of Science ®Google Scholar
• KnudsonRJConstantineHPAn effect of isoproterenol on ventilation-perfusion in asthmatic versus normal subjectsJ Appl Physiol19672234024066020222
   PubMed Web of Science ®Google Scholar
• WagnerPDDantzkerDRIacovoniVETomlinWCWestJBVentilation-perfusion inequality in asymptomatic asthmaAm Rev Respir Dis19781183511524707879
   PubMed Web of Science ®Google Scholar
• PhilipsonLHBeta-agonists and metabolismJ Allergy Clin Immunol2002110Suppl 6S313S31712464941
   PubMedGoogle Scholar
• TesfamariamBWaldronTSeymourAAQuantitation of tremor in response to beta-adrenergic receptor stimulation in primates: relationship with hypokalemiaJ Pharmacol Toxicol Methods199840420120510465154
   PubMed Web of Science ®Google Scholar
• KelleherDLMehtaRSJean-FrancoisBMSafety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trialPLoS One2012712e5071623284643
   PubMed Web of Science ®Google Scholar
• KelleherDTombsLCraterGPreeceABrealeyNMehtaRA placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects [Abstract]Am J Respir Crit Care Med2013187A1487
   Web of Science ®Google Scholar
• MehtaRKelleherDPreeceAHughesSCraterGEffect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label studyInt J Chron Obstruct Pulmon Dis2013815916723569370
   PubMed Web of Science ®Google Scholar
• MehtaRHardesKKelleherDPreeceATombsLBrealeyNEffect of moderate hepatic impairment (MHI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK) [Abstract]Eur Respir J201342Suppl 57A3641
   Google Scholar
• KelleherDHardesKBrealeyNTombsLPreeceAMehtaREffect of severe renal impairment (SRI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK) [Abstract]Eur Respir J201342Suppl 57P4148
   Google Scholar
• FeldmanGWalkerRRBrooksJMehtaRCraterG28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trialPulm Pharmacol Ther201225646547122955035
   PubMed Web of Science ®Google Scholar
• DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespir Med2013107101538154623830094
   PubMed Web of Science ®Google Scholar
• CelliBRCraterGKilbrideSA 24-week randomized, double-blind, placebo-controlled study of the efficacy and safety of once-daily umeclidinium/vilanterol 125/25 mcg in COPD [Abstract]Am J Respir Crit Care Med2013187A2435
   Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
   PubMed Web of Science ®Google Scholar
• clinicaltrials.gov [homepage on the Internet]DB2113374: a multicenter trial comparing the efficacy and safety of GSK573719/GW642444 with GSK573719 and with tiotropium over 24 weeks in subjects with chronic obstructive pulmonary disease (COPD). ClinicalTrials.gov identifier NCT13169132011 [updated January 9, 2014]. Available from: http://clinicaltrials.gov/show/NCT1316913Accessed May 18, 2014
   Google Scholar
• clinicaltrials.gov [homepage on the Internet]A 52 week, multi-centre, open-label study to evaluate the safety and tolerability of GSK573719/GW642444 125 mcg once-daily in combination with GW642444 25 mcg once-daily via novel dry powder inhaler (nDPI) in Japanese subjects with chronic obstructive pulmonary disease. ClinicalTrials.gov identifier NCT13763882011 [updated February 13, 2014]. Available from: http://clinicaltrials.gov/show/NCT1376388Accessed May 18, 2014
   Google Scholar
• FDA Advisory Committee Briefing DocumentANORO™ ELLIPTA™ (Umeclidinium Bromide/Vilanterol Inhalation Powder) For Treatment of Chronic Obstructive Pulmonary Disease Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM367414.pdfAccessed May 28, 2014
   Google Scholar
• PrakashABabuKSMorjariaJBNovel anti-cholinergics in COPDDrug Discov Today20131821–221117112623872011
   PubMed Web of Science ®Google Scholar
• CazzolaMSegretiAMateraMGNew developments in the combination treatment of COPD: focus on umeclidinium/vilanterolDrug Des Devel Ther2013712011208
   PubMed Web of Science ®Google Scholar
• FeldmanGJEdinAThe combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospectsTher Adv Respir Dis20137631131924004659
   PubMed Web of Science ®Google Scholar